The genomics of heart failure: design and rationale of the HERMES consortium
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The genomics of heart failure : design and rationale of the HERMES consortium. / Regeneron Genetics Center.
In: ESC heart failure, Vol. 8, No. 6, 2021, p. 5531-5541.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The genomics of heart failure
T2 - design and rationale of the HERMES consortium
AU - Lumbers, R Thomas
AU - Shah, Sonia
AU - Lin, Honghuang
AU - Czuba, Tomasz
AU - Henry, Albert
AU - Swerdlow, Daniel I
AU - Mälarstig, Anders
AU - Andersson, Charlotte
AU - Verweij, Niek
AU - Holmes, Michael V
AU - Ärnlöv, Johan
AU - Svensson, Per
AU - Hemingway, Harry
AU - Sallah, Neneh
AU - Almgren, Peter
AU - Aragam, Krishna G.
AU - Asselin, Geraldine
AU - Backman, Joshua D.
AU - Biggs, Mary L
AU - Bloom, Heather L.
AU - Boersma, Eric
AU - Brandimarto, Jeffrey
AU - Brown, Michael R.
AU - Brunner-La Rocca, Hans-Peter
AU - Carey, David J
AU - Chaffin, Mark D.
AU - Chasman, Daniel I.
AU - Chazara, Olympe
AU - Chen, Xing
AU - Chen, Xu
AU - Chung, Jonathan H.
AU - Chutkow, William
AU - Cleland, John G F
AU - Cook, James P
AU - de Denus, Simon
AU - Dehghan, Abbas
AU - Delgado, Graciela E
AU - Denaxas, Spiros
AU - Doney, Alexander S.
AU - Dörr, Marcus
AU - Dudley, Samuel C.
AU - Engström, Gunnar
AU - Esko, Tõnu
AU - Fatemifar, Ghazaleh
AU - Felix, Stephan B
AU - Finan, Chris
AU - Køber, Lars
AU - Stender, Steen
AU - Regeneron Genetics Center
N1 - Publisher Copyright: © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2021
Y1 - 2021
N2 - Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
AB - Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34–90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01–0.05) at P < 5 × 10−8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
U2 - 10.1002/ehf2.13517
DO - 10.1002/ehf2.13517
M3 - Journal article
C2 - 34480422
AN - SCOPUS:85114632006
VL - 8
SP - 5531
EP - 5541
JO - E S C Heart Failure
JF - E S C Heart Failure
SN - 2055-5822
IS - 6
ER -
ID: 301630483